Does Wellcare Cover Jardiance?
The verdict
Covered on most plans
Yes — Wellcare (Centene) covers Jardiance on its 2026 Medicare Part D plans (Value Script and Classic PDPs) and Medicaid managed-care plans. As a Part D sponsor, Wellcare is legally required to carry Jardiance at the IRA negotiated Maximum Fair Price of $197 per 30-day supply, effective January 1, 2026. On Medicare, prior authorization and step therapy are essentially nil. On Wellcare Managed Medicaid, metformin-first step therapy is the most common hurdle — document prior metformin use and the coverage process is straightforward.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Wellcare using your member ID.
Key facts
Jardiance coverage on Medicare Part D is near-universal: 99.9% nationally; prior authorization is required on only 0% of Medicare plans, making it one of the lowest-UM branded drugs in the tier (MMIT, Aug 8, 2025).
MMIT via GoodRx (as of Aug 8, 2025)
The 2026 IRA Maximum Fair Price for Jardiance is $197 per 30-day supply — a 66% reduction from the prior list price of approximately $573; all Wellcare Part D plans must apply this price.
CMS Medicare Drug Price Negotiation Program, 2026 MFP
Wellcare Managed Medicaid commonly requires metformin-first step therapy for Jardiance: 25.5% of Medicaid plans nationally require PA and 22.9% require step therapy for this SGLT2 inhibitor (MMIT, Aug 8, 2025).
MMIT via GoodRx (as of Aug 8, 2025)
Medicare vs. commercial coverage
Whether Wellcare covers Jardiance depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Jardiance is covered on Wellcare's 2026 Medicare Part D plans — Value Script and Classic PDPs — typically as a Tier 3 preferred brand. Prior authorization and step therapy on Medicare are remarkably low for Jardiance: nationally 0% PA and only 0.1% step therapy (MMIT, as of Aug 8, 2025). As a Part D sponsor, Wellcare must apply the IRA negotiated Maximum Fair Price of $197 per 30-day supply, effective January 1, 2026 (a 66% reduction from the prior list price of approximately $573). Boehringer Ingelheim reports that approximately 84% of Medicare Part D patients pay $0–$50 per month for Jardiance and roughly 16% average about $166 — these are manufacturer-reported averages, not guaranteed cost-shares for any specific plan. Wellcare's cost architecture for Part D is: a $615 annual deductible (the maximum under the 2026 CMS Part D redesign), then Tier 3 cost-share in the initial coverage phase, with a $2,100 annual out-of-pocket cap. Wellcare's 5–6 tier structure (Tier 1 preferred generic $0 at preferred pharmacy; Tier 3 preferred brand; a separate Tier 6 for select chronic-condition drugs) means you should confirm which tier Jardiance sits on your specific Wellcare plan. LIS/Extra Help enrollees pay $0–$12.65 per month. Medicare beneficiaries cannot use the Boehringer Ingelheim commercial savings card.
Commercial / Employer
Group & marketplace plans
Wellcare's commercial and ACA footprints are limited relative to its Medicare Part D and Medicaid MCO operations. Where Wellcare commercial or ACA plans are offered, Jardiance is covered for its on-label indications — nationally 99.7% commercial and 99.9% ACA coverage (MMIT, Aug 8, 2025). Commercial step therapy is the critical nuance: 38.9% of commercial plans nationally require a metformin-first step for Jardiance (MMIT, Aug 8, 2025). Wellcare's limited commercial presence means this affects fewer members, but if you have a Wellcare commercial plan and receive a step-therapy denial, your prescriber should document maximum-tolerated metformin use or a clinical contraindication. ACA plans carry possible step therapy (27.7% nationally). Verify your specific plan. Wellcare Managed Medicaid covers Jardiance, but prior authorization and metformin-first step therapy are common: nationally 25.5% PA and 22.9% step therapy in Medicaid for Jardiance (MMIT, Aug 8, 2025). The Boehringer Ingelheim savings card (~$10 per fill) is available for commercially insured patients not enrolled in a government program.
The 3 boxes you must tick to get approved
Commercial plans that will consider Jardiance require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 3 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Jardiance actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Approximately $600 or more per 30-day supply at retail pharmacy (pharmacy-variable estimate). No generic empagliflozin is currently available.
List price with no coverage — before any manufacturer savings card.
With coverage
Medicare Part D (Wellcare Value Script/Classic): $615 annual deductible; then Tier 3 cost-share; IRA Maximum Fair Price $197 per 30-day supply effective January 1, 2026; approximately 84% of Part D patients pay $0–$50 per month (Boehringer Ingelheim, manufacturer-reported average — not guaranteed); $2,100 annual out-of-pocket cap. LIS/Extra Help: $0–$12.65 per month. Medicaid: $0–$10 typical. Commercial (where offered): Boehringer Ingelheim savings card ~$10 per fill (commercially insured, non-government patients). All figures are estimates — verify with your specific Wellcare plan.
Typical monthly copay once prior authorization is approved.
All dollar figures are estimates. Your actual cost depends on your Wellcare plan's tier structure, deductible status, and benefit phase. The $615 deductible must be met before cost-sharing applies in the initial coverage phase. The Boehringer Ingelheim $0–$50 Part D cost band is a manufacturer-reported average — not a guarantee for your specific plan. Confirm cost-share on the Wellcare formulary. Medicare beneficiaries cannot use the Boehringer Ingelheim commercial savings card.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Look up Jardiance on the Wellcare plan formulary tool
Visit Wellcare.com and use the drug pricing or formulary search for your 2026 plan (Value Script, Classic PDP, or Medicaid plan). Search for Jardiance or empagliflozin to find the tier, any prior authorization or step therapy requirement, and estimated cost-share. Confirm whether your plan uses a fixed copay or coinsurance for Tier 3 drugs.
- 2
Have your prescriber document metformin history before Medicaid or commercial PA
If you are on Wellcare Managed Medicaid or a Wellcare commercial plan, a metformin-first step therapy requirement is common. Ask your prescriber to include documentation of prior metformin use (dose, duration, and reason for discontinuation or contraindication) with the prescription. This is the standard evidence needed to satisfy the step-therapy requirement and should resolve most coverage requests without an extended appeals process.
- 3
Contact Wellcare member services to verify your deductible status and tier
Call the number on the back of your Wellcare ID card. Ask: (1) Has my $615 deductible been met? (2) Which tier is Jardiance on my plan? (3) Is prior authorization or step therapy required for my specific plan? Having your plan ID and Jardiance dosage (10 mg or 25 mg) ready will speed up the lookup.
Options if Wellcare won't cover Jardiance
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Farxiga (dapagliflozin) generic
A generic for dapagliflozin (Farxiga) is already available, likely at lower cost-share than Jardiance on Wellcare plans. Discuss with your prescriber whether generic dapagliflozin is appropriate for your indication (T2D, heart failure, or CKD).
Metformin (generic)
First-line oral diabetes medication; Tier 1 at approximately $4 per month cash price. If Wellcare's step therapy requires metformin first, your prescriber will document this before approving Jardiance. Metformin is also available on the Wellcare formulary at very low cost-share.
Januvia (sitagliptin) / generic sitagliptin
A DPP-4 inhibitor for type 2 diabetes. Generic sitagliptin launched May 2026 (Sandoz), offering lower cost-share. Discuss with your prescriber whether a DPP-4 inhibitor fits your clinical needs compared to an SGLT2 inhibitor.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Yes — Wellcare (Centene) covers Jardiance on its 2026 Medicare Part D plans (Value Script and Classic PDPs) and Medicaid managed-care plans, typically as a Tier 3 preferred brand. On Medicare, prior authorization is essentially zero (0% PA, 0.1% step nationally per MMIT, Aug 8, 2025). On Wellcare Medicaid, metformin-first step therapy is common (25.5% PA, 22.9% step nationally). The 2026 IRA negotiated Maximum Fair Price is $197 per 30-day supply.
Yes, in most states. Wellcare Managed Medicaid commonly applies a metformin-first step therapy: your prescriber must document that you have tried metformin at the maximum tolerated dose or that it is contraindicated (e.g., renal impairment). Nationally, 25.5% of Medicaid plans require PA and 22.9% require step therapy for Jardiance (MMIT, Aug 8, 2025). Once metformin use is documented, the PA process is typically straightforward. Verify requirements on your state's Preferred Drug List.
CMS negotiated a Jardiance Maximum Fair Price of $197 per 30-day supply, effective January 1, 2026 — a 66% reduction from the prior list price of approximately $573. All Wellcare Part D plans must apply this price. However, the MFP is a payer-side ceiling — your actual copay depends on Wellcare's Tier 3 cost-sharing structure for your specific plan. The $2,100 annual Part D out-of-pocket cap ensures that your total drug spending is limited in 2026 even if you are in a coinsurance-based plan.
Most Wellcare 2026 Part D plans carry the maximum allowable deductible of $615. Until you satisfy this deductible, you pay the full negotiated cost for non-exempt tiers at the pharmacy — including Jardiance. After the deductible, your Tier 3 cost-share applies. Boehringer Ingelheim reports that approximately 84% of Medicare Part D patients pay $0–$50 per month for Jardiance (manufacturer-reported average). The $2,100 annual cap limits your total out-of-pocket exposure. Confirm your deductible status with Wellcare member services.
Only if you have a Wellcare commercial plan — not Medicare or Medicaid. The Boehringer Ingelheim savings card (~$10 per fill) is available for commercially insured patients not enrolled in any government health program. If you have Wellcare Medicare Part D, Medicare Advantage, or Managed Medicaid, you cannot use the savings card. LIS/Extra Help enrollees may pay $0–$12.65 per month through the federal subsidy program instead.
Related Articles
Does Aetna Cover Vyvanse? 2026 CVS Caremark Formulary
Aetna covers Vyvanse via CVS Caremark — generic lisdexamfetamine preferred, brand non-preferred. 70 mg/day QL per Policy 5.60.024; age-22 PA required.
Read moreDoes Aetna Cover Prolia? CVS Caremark Medical Benefit | Curex
Aetna covers Prolia under the medical benefit with PA — a q6-month clinic injection, not Part D. Jubbonti biosimilar now preferred on CVS Caremark.
Read moreDoes Anthem Cover Adderall? 2026 Coverage Guide | Curex
Anthem covers Adderall through CarelonRx — generic preferred, brand non-preferred. Step therapy may apply on some plans. Verify your Anthem plan.
Read moreDoes Anthem Cover Contrave? 2026 Brand Coverage Guide | Curex
Anthem covers Contrave only if your plan has a weight-loss benefit. Many plans carve it out. CurAccess ~$99/mo is often the fastest path.
Read moreDoes Aetna Cover Contrave? 2026 CVS Caremark Guide | Curex
Aetna (CVS Caremark) often excludes Contrave under AOM carve-outs. Where covered, CVS BMI prior auth applies. Medicare bars it by law. CurAccess ~$99/mo.
Read moreDoes Aetna Cover Forteo? 2026 Coverage Guide
Aetna (CVS) often excludes brand Forteo in favor of generic teriparatide or Bonsity. Teriparatide is covered with PA and bisphosphonate step therapy. 2026.
Read moreThis content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Wellcare before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.